|
18 Feb
Posted by Sensei @ 3:37 am on Sunday, February 18th, 2007 in Stock Comments
Within the last two months, Possis Medical, received two FDA approvals. The first one in December was for their new version of their AngioJet device.
Dec 18, 2006 Possis Medical Inc., POSS, said Monday it has received marketing approval from the Food and Drug Administration for its AngioJet Ultra Thrombectomy System, the next-generation version of the AngioJet Rheolytic Thrombectomy System. AngioJet is marketed for blood clot removal from arterial and venous blood vessels. A full-market release is expected by summer of 2007.
Jan 30, 2007: Possis Medical Inc., POSS, late Tuesday said the Food and Drug Administration has approved the marketing of its AngioJet Spiroflex rapid exchange catheter to remove blood clots from coronary arteries. The Spiroflex catheter is specifically designed for blood clot removal in small vessels such as coronary arteries, the Minneapolis-based medical device company said. The Spiroflex catheter is now approved for sale in the United States and in overseas markets for both peripheral and coronary use, the company said.
Well I recently obtained a blood clot, in my leg, a DVT aka Deep Vein Thrombosis. I got it on a ski trip and probably clotted up on the flight home-so says my doctors. Well one of the potential procedures that was proposed was this procedure where they slip a catheter in the vein and spray it with a fluid then “zip it out.” I was told it was the latest thing with DVT’s. It is an endovascular procedure and its done on an outpatient basis. Normally for DVT’s you are put on Coumadin and/or Lovenox and have to let it dissolve over time (often 3 months). Sometimes if a clot is not treated in time a piece of the clot can be “absorbed” by the vein wall and create a bump in the vein. That bump can potentially be a big problem down the road and cause a thrombotic event. The new AngioJet’s purpose is to break up and remove clots. The patient wouldn’t have that long term problem. This also probably means less time on Coumadin and Lovenox for the patient which my doctors tell me aren’t that great for the body. Note: I am still on Coumadin and did take Lovenox in the first week+ of my clot.
So I’m going through stocks tonight looking for certain technical/fundamental patterns and I find POSS. It looks good on a technical basis and then I go and find out what they do. Is it a serendipitous event? Nobody seems to be talking about this stock at all online.
A very good “mini-presentation” from the CEO of Possis can be found with this link talking about the recent studies of drug coated stents vs what the AngioJet system does.
Tags: blood-clot, dvt, poss, Stock Comments
View Comments
Sensei
July 15th, 2008 at 9:37 am
1The company Possis Medical was taken over by Bayer AG.
Alan Poland
September 23rd, 2008 at 1:41 pm
2Sensei,
My name is Alan Poland. I am one of the Clinical Sales Representatives for what is now called Medrad Interventional / Possis. Possis Medical was recently acquired and merged with Medrad…a Bayer Medical Company.
I handle not only the clinical side of the use of AngioJet (the device that removed your blood clot) but I also assist with marketing the product and selling it in the Arizona and Utah areas. I have a vast history of clinical experience in the Cardiac Cath Lab and Interventional Radiology areas of hospitals.
As you can see, there is a bit more information getting out about DVT and more and more physicians are talking about it. An estimated 600,000 cases of DVT occur in the United States, affecting both men and women in all ethnic and social groups so. DVT can lead to complications such as pulmonary embolism (PE) or post-thrombotic syndrome (PTS). Approximately 200,000 individuals die annually as a result of pulmonary embolism.
I personally feel your frustration about the treatment of DVT and becoming more aggressive with treating DVT. By performing mechanical thrombectomy on patients with DVT, the patient can potentially spend half if not less than half the time in hospital with better results. The key is to identify and diagnose the phenomena early. I have attached a website for you to reference:
http://vasculardiseasemanagement.com/article/3236
Lastly, AngioJet is used to treat all peripheral arterial vessels that contain clot as well as Coronary arteries. Nephrologists and Interventional Radiologists use the AngioJet to treat A/V fistulea that renal dialysis patients have for their dialysis treatments.
As for stock, Possis Medical is now officially merged with Medrad and are not publicly traded on the stock market any longer.
If you have any more questions or would like more information on the use of AngioJet and its applications in thrombus management, please feel free to contact myself or anyone at the Medrad Interventional / Possis offices. Dan Janse would be an excellent point of contact for your peripheral application questions.
I have also attached a great website that Medrad Interventional / Possis sponsors in order to help educate our communities and hospital personnel on DVT. The website is:
http://www.dvtanswers.com/index.html
Thanks so much,
Alan Poland
480-600-6984
StockRake
September 24th, 2008 at 9:23 am
3Thanks for all the great info Alan.
crystal scott
October 8th, 2008 at 1:01 pm
4Great Job Alan,
My name is: Crystal Scott Clinical Sales Rep. for MedRad Interventional/ Possis
I also have pushed for this program in the Jacksonville, Fl area. If anyone should read this blog please contact me:
904-703-9283
I would be happy to help in my area.
crystal scott
October 8th, 2008 at 5:01 pm
5Great Job Alan,
My name is: Crystal Scott Clinical Sales Rep. for MedRad Interventional/ Possis
I also have pushed for this program in the Jacksonville, Fl area. If anyone should read this blog please contact me:
904-703-9283
I would be happy to help in my area.
RSS feed for comments on this post · TrackBack Website (noto required)
Leave a reply
StockRake.com's Most Popular Posts
StockRake Tweets
Past Posts
Recent Posts
Space
Favorite Posts
© 2009 Stock Rake – Index trading, etf trading, and finding new swing trade opportunities XML Feed Crawl | Credits